Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Edurant Ped (rilpivirine) for the treatment of HIV-1 in combination with other antiretroviral (ARV) therapies in treatment-naive children aged at least 2 years and weighing between 14 and 25 kg.

This approval builds on Johnson & Johnson's long-standing commitment to ensuring that people living with HIV, including children, have treatment options that can work for them.

' Although the population of young children living with HIV is small, additional treatment options remain essential to ensure that every person living with HIV can benefit from a treatment regimen that works for them,' commented Penny Heaton, M.D., Global Therapeutic Area Manager, Infectious Diseases. and Vaccines at Johnson & Johnson.

Copyright (c) 2024 CercleFinance.com. All rights reserved.